Lv3
310 积分 2023-07-11 加入
Dupilumab Reduces Inflammatory Biomarkers in Patients Aged 6 Months to 18 Years With Moderate-to-Severe or Severe Atopic Dermatitis
1年前
已完结
Dupilumab Efficacy in Children With Atopic Dermatitis Aged 6 Months to 5 Years With and Without Atopic Comorbidities
1年前
已完结
34297 Dupilumab provides long-term improvement in sleep loss in children, adolescents, and adults with atopic dermatitis
1年前
已完结
O04: Efficacy and safety of dupilumab in children aged ≥ 6 months to < 6 years with moderate‐to‐severe atopic dermatitis
1年前
已完结
Efficacy and safety of dupilumab treatment with concomitant topical corticosteroids in children aged 6 months to 5 years with severe atopic dermatitis
1年前
已完结
Dupilumab treatment results in rapid, sustained and clinically meaningful improvement in itch in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis
1年前
已完结
Dupilumab treatment reduces total IgE levels in patients 6 months and older with moderate-to-severe atopic dermatitis
1年前
已完结
Dupilumab Treatment Shows Rapid and Consistent Improvement in Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years
1年前
已完结
Dupilumab treatment in adult patients is efficacious regardless of age at atopic dermatitis onset
1年前
已完结
皖公网安备34019202002308
